Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (26 ops.)
Latest filing published 08 Oct 2026 for Rapport Therapeutics, Inc., €96k. Read the official filing
Filing timeline
BuySaleAbraham Ceesay
Insider track record
Disclosed buys
0
Disclosed sells
26
Signal history
Abraham Ceesay: trading record in brief
This profile gathers the share dealings of Abraham Ceesay across 4 companies, led by Rapport Therapeutics, Inc., Cerevel Therapeutics Holdings, Inc. and Pacira BioSciences, Inc. Between 5 August 2022 and 7 October 2026, the trades on record add up to 33 filings.
No open-market purchase appears, only 26 sales worth €5.2M. The amount is not disclosed for 2 filings. The rest of the record consists of 3 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 21 sales.
The newest entry dates from 8 October 2026: an open-market sale of €96k, in Rapport Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Abraham Ceesay
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations33 total
3,375 shares@ US$32.0314Common StockSEC:0001193125-26-417919:0
1,147 shares@ US$30.66Common StockSEC:0001193125-26-417919:1
1,952 shares@ US$39.05230.0047% mcap1.3% of flowCommon StockSEC:0001193125-26-401017:0
215 shares@ US$39.86020.0005% mcap0.1% of flowCommon StockSEC:0001193125-26-401017:1
43 shares@ US$41.050.0001% mcap0.0% of flowCommon StockSEC:0001193125-26-401017:2
7,141 shares@ US$45.5550.020% mcap5.6% of flowCommon StockSEC:0001193125-26-386436:0
1,069 shares@ US$46.01470.0030% mcap0.8% of flowCommon StockSEC:0001193125-26-386436:1
18,921 shares@ US$49.57230.056% mcap16.1% of flowCommon StockSEC:0001193125-26-368285:0
14,171 shares@ US$45.97360.039% mcap11.3% of flowCommon StockSEC:0001193125-26-346995:0
8,370 shares@ US$46.74790.024% mcap6.8% of flowCommon StockSEC:0001193125-26-346995:1
3,664 shares@ US$46.89880.010% mcap3.0% of flowCommon StockSEC:0001193125-26-346995:2
19,500 shares@ US$48.04340.057% mcap16.2% of flowCommon StockSEC:0001193125-26-346995:3
5,794 shares@ US$48.62290.017% mcap4.9% of flowCommon StockSEC:0001193125-26-346995:4
2,203 shares@ US$42.1070.0057% mcap1.6% of flowCommon StockSEC:0001193125-26-323637:0
7 shares@ US$42.7350.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-323637:1
5,481 shares@ US$39.72170.013% mcap3.8% of flowCommon StockSEC:0001193125-26-304786:0
2,729 shares@ US$40.57240.0068% mcap1.9% of flowCommon StockSEC:0001193125-26-304786:1
876 sharesCommon StockSEC:0001193125-26-292519:1
7,344 sharesCommon StockSEC:0001193125-26-292519:0
3,552 shares@ US$29.05161.7% of flowCommon StockSEC:0001193125-26-059886:0
5,833 shares@ US$26.11582.6% of flowCommon StockSEC:0001193125-26-019820:0
2,441 shares@ US$28.83781.2% of flowCommon StockSEC:0001193125-25-324826:0
2,777 shares@ US$24.92461.2% of flowCommon StockSEC:0001193125-25-286218:0
4,647 shares@ US$25.7242.1% of flowCommon StockSEC:0001193125-25-241472:0
39,435 shares@ US$26.29917.6% of flowCommon StockSEC:0001193125-25-209062:0
25 of 33 declarations
